News

The new data builds on earlier work by lead investigator, Kenneth Shindler in the same preclinical model showing that activation of the SIRT1 enzyme with SRT501 is neuroprotective

The data suggests that the use of company’s biomarkers could help better identify women with ovarian cancer, as well as improve the detection of early-stage disease. A clinical

The study will be conducted in France and is designed as a two-stage study with potential enrolment of up to 27 patients. The primary endpoint will be the

Dyloject will be available at the National Health Service tariff price of GBP48 per pack (10 x 75mg/2ml vials). The SMC has said that the manufacturer’s submission related

Under the term sheet, Medpharm will be acquired for $1.5 million. Symbollon will acquire approximately 64% of the company in a stock swap for Symbollon shares and acquire

Bard’s Access Systems subsidiary, located in Salt Lake City, Utah, will assume marketing responsibility for the related products. The company expects to complete the transaction following approval by

New investor MedImmune Ventures joined previous investors Bay City Capital, Oxford Bioscience Partners, Technology Partners, Pappas Ventures and Neuro Ventures in the round. As a part of the

In this trial, single agent SNS-595 has demonstrated disease control (defined as stable disease, partial response or complete response) in 31 of 35 patients evaluable for best response

This IV Busulfex is an oncology product marketed and sold in the US and Canada, and through distributors in a number of other countries. Otsuka will oversee the